ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Acquisition of Ciprofloxacin Resistance Among an Expanding Clade of β-Lactamase-Positive, Serogroup Y Neisseria meningitidis in the United States.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Meningococcal Disease in Older Adults: Challenges in Diagnosis and Management.Infectious diseases and therapy · 2026Review
- Serogroup Switching inThe New England journal of medicine · 2026Article
- Meningococcal carriage in UK university students post-pandemic: evidence for MenACWY vaccine impact and ongoing genogroup B risk.Frontiers in public health · 2026Article
- Emergence ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Genomic characterization of invasiveEmerging microbes & infections · 2025Article
- Understanding the value of meningococcal vaccination for adolescents and young adults in the United States: insights from a steady-state modelling approach.BMC public health · 2025Article
- Progression of antibiotic resistance inClinical microbiology reviews · 2025Review
- Genetic variability inIJID regions · 2025Article
- A Pediatric Case of Serogroup Y Meningococcal Meningitis in a 12-Year-Old Boy Combined with Respiratory Infection of Three Species of Viruses in China.Infection and drug resistance · 2025Article
- Article
- Selection of Antibiotics as Prophylaxis for Close Contacts of Patients with Meningococcal Disease in Areas with Ciprofloxacin Resistance - United States, 2024.MMWR. Morbidity and mortality weekly report · 2024Article
- Penicillin and Cefotaxime Resistance of Quinolone-Resistant Neisseria meningitidis Clonal Complex 4821, Shanghai, China, 1965-2020.Emerging infectious diseases · 2023Article
- Meningococcal disease in North America: Updates from the Global Meningococcal Initiative.The Journal of infection · 2022Review
- Ciprofloxacin Concentrations 1/1000th the MIC Can Select for Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2022Article
- Enhancing Meningococcal Genomic Surveillance in the Meningitis Belt Using High-Resolution Culture-Free Whole-Genome Sequencing.The Journal of infectious diseases · 2022Article
- Serogroup Y Clonal Complex 23 Meningococcus in China Acquiring Penicillin Resistance from Commensal Neisseria lactamica Species.Antimicrobial agents and chemotherapy · 2022Article
- Antimicrobial Susceptibility Survey of Invasive Neisseria meningitidis, United States 2012-2016.The Journal of infectious diseases · 2022Article
- Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review.The Journal of infection · 2022Review
- Molecular detection of fluoroquinolone-resistantFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPenicillin and ciprofloxacin are important for invasive meningococcal disease (IMD) management and prevention. IMD cases caused by penicillin- and ciprofloxacin-resistant Neisseria meningitidis containing a ROB-1 β-lactamase gene (blaROB-1) and a mutated DNA gyrase gene (gyrA) have been recently reported in the United States.
methodsWe examined 2097 meningococcal genomes collected through US population-based surveillance from January 2011 to February 2020 to identify IMD cases caused by strains with blaROB-1- or gyrA-mediated resistance. Antimicrobial resistance was confirmed phenotypically. The US isolate genomes were compared to non-US isolate genomes containing blaROB-1. Interspecies transfer of ciprofloxacin resistance was assessed by comparing gyrA among Neisseria species.
resultsEleven penicillin- and ciprofloxacin-resistant isolates were identified after December 2018; all were serogroup Y, sequence type 3587, clonal complex (CC) 23, and contained blaROB-1 and a T91I-containing gyrA allele. An additional 22 penicillin-resistant, blaROB-1- containing US isolates with wild-type gyrA were identified from 2013 to 2020. All 33 blaROB-1-containing isolates formed a single clade, along with 12 blaROB-1-containing isolates from 6 other countries. Two-thirds of blaROB-1-containing US isolates were from Hispanic individuals. Twelve additional ciprofloxacin-resistant isolates with gyrA T91 mutations were identified. Ciprofloxacin-resistant isolates belonged to 6 CCs and contained 10 unique gyrA alleles; 7 were similar or identical to alleles from Neisseria lactamica or Neisseria gonorrhoeae.
conclusionsRecent IMD cases caused by a dual resistant serogroup Y suggest changing antimicrobial resistance patterns in the United States. The emerging dual resistance is due to acquisition of ciprofloxacin resistance by β-lactamase-containing N. meningitidis. Routine antimicrobial resistance surveillance will effectively monitor resistance changes and spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.